Back to Agenda
Applying Principles of Global Regulatory Collaboration to Address Chronic Disease
Session Chair(s)
Brad Jordan, PHD
Associate Vice President, Regulatory Policy and Strategy
Eli Lilly and Company, United States
This session will focus on assessing the effectiveness of current regulatory collaboration efforts and identifying how those principles can be applied to chronic disease areas outside of oncology, such as metabolic disease and obesity.
Learning Objective : Describe the impact of global regulatory collaboration on patient outcomes; Discuss risks associated with chronic disease and its impact on society as a whole; Identify innovative ways to address chronic disease through regulatory innovation and collaboration.
Speaker(s)
Project ORBIS and ACCESS Experience
Melissa Hunt, MSC
Health Canada, Canada
Director
Panelist
Julian Beach
Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
Interim Executive Director, Healthcare Quality and Access
Panelist
Magda Bujar, PHD, MSC
Centre for Innovation in Regulatory Science (CIRS), United Kingdom
Associate Director, Regulatory Programme and Strategic Partnerships
Applying Learnings from Project ORBIS
R. Angelo De Claro, MD
FDA, United States
Deputy Director (Acting), Oncology Center of Excellence
Industry Perspective
Laura Bloss, PHD
Amgen, Inc., United States
Vice President Global Regulatory Affairs
Have an account?